Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytyc UK boosted by regio's ThinPrep LBC decision:

This article was originally published in Clinica

Executive Summary

Cytyc UK's bid to increase its stake in the national cervical screening market received a boost this week, following the decision by the Southwest region of the National Health Service (NHS) to use the company's ThinPrep liquid-based cytology (LBC) test in all its cervical screening programmes. The decision is to be implemented in all the region's 13 laboratories, which perform some 360,000 tests a year. Over the next five years, these will total an estimated 1.8 million tests. The decision follows a pilot implementation project at Bristol's Southmead Hospital. The technology also received the approval in August 2003 of the National Institute for Clinical Excellence (see Clinica No 1071, p 5). NHS Southwest incorporates the Strategic Health Authorities of Avon, Gloucester & Wiltshire, Devon & Somerset and the South West Peninsula.

You may also be interested in...



US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.

Topics

UsernamePublicRestriction

Register

MT058758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel